JPWO2022133239A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022133239A5 JPWO2022133239A5 JP2023536859A JP2023536859A JPWO2022133239A5 JP WO2022133239 A5 JPWO2022133239 A5 JP WO2022133239A5 JP 2023536859 A JP2023536859 A JP 2023536859A JP 2023536859 A JP2023536859 A JP 2023536859A JP WO2022133239 A5 JPWO2022133239 A5 JP WO2022133239A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- immunoglobulin protein
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 80
- 108060003951 Immunoglobulin Proteins 0.000 claims 67
- 102000018358 immunoglobulin Human genes 0.000 claims 67
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 34
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 34
- 239000003795 chemical substances by application Substances 0.000 claims 33
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 claims 27
- 108010038640 atrial natriuretic factor receptor A Proteins 0.000 claims 27
- 239000003814 drug Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 20
- 239000000556 agonist Substances 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000012986 modification Methods 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 230000000004 hemodynamic effect Effects 0.000 claims 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 229940124572 antihypotensive agent Drugs 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims 2
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical group COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 229960001094 midodrine Drugs 0.000 claims 1
- 230000029865 regulation of blood pressure Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127959P | 2020-12-18 | 2020-12-18 | |
| US63/127,959 | 2020-12-18 | ||
| PCT/US2021/064073 WO2022133239A1 (en) | 2020-12-18 | 2021-12-17 | Immunoglobulin proteins that bind to npr1 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503784A JP2024503784A (ja) | 2024-01-29 |
| JPWO2022133239A5 true JPWO2022133239A5 (enExample) | 2024-12-24 |
Family
ID=79687048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536859A Pending JP2024503784A (ja) | 2020-12-18 | 2021-12-17 | Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12325752B2 (enExample) |
| EP (1) | EP4263616A1 (enExample) |
| JP (1) | JP2024503784A (enExample) |
| KR (1) | KR20230132468A (enExample) |
| CN (1) | CN116964101A (enExample) |
| AU (1) | AU2021401415A1 (enExample) |
| CA (1) | CA3202629A1 (enExample) |
| CL (1) | CL2023001680A1 (enExample) |
| CO (1) | CO2023009498A2 (enExample) |
| IL (1) | IL303542A (enExample) |
| MX (1) | MX2023007023A (enExample) |
| WO (1) | WO2022133239A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| IL303542A (en) | 2020-12-18 | 2023-08-01 | Regeneron Pharma | Immunoglobulin proteins that bind to NPR1 agonists |
| CN118159290A (zh) * | 2021-10-11 | 2024-06-07 | 瑞泽恩制药公司 | 通过施用抗npr1抗体来影响血液动力学变化的方法 |
| MX2024006812A (es) * | 2021-12-06 | 2024-08-19 | Regeneron Pharma | Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos. |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7879544B2 (en) | 2002-07-29 | 2011-02-01 | Hmgene Inc. | Methods of identifying adipocyte specific genes, the genes identified, and their uses |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US20100310561A1 (en) | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| WO2010065293A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| ES2865648T3 (es) | 2009-06-26 | 2021-10-15 | Regeneron Pharma | Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa |
| ES2603559T5 (es) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Cadena ligera común de ratón |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| CA2818287C (en) | 2012-06-08 | 2021-11-02 | Brock University | A method of activating immune response in plants |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2016131943A1 (en) | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| EP3529278A1 (en) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| EP3898700A1 (en) * | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| CN119613549A (zh) * | 2019-06-12 | 2025-03-14 | 诺华股份有限公司 | 利钠肽受体1抗体及使用方法 |
| WO2022130182A1 (en) | 2020-12-14 | 2022-06-23 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| IL303542A (en) | 2020-12-18 | 2023-08-01 | Regeneron Pharma | Immunoglobulin proteins that bind to NPR1 agonists |
| MX2024006812A (es) | 2021-12-06 | 2024-08-19 | Regeneron Pharma | Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos. |
-
2021
- 2021-12-17 IL IL303542A patent/IL303542A/en unknown
- 2021-12-17 EP EP21844504.7A patent/EP4263616A1/en active Pending
- 2021-12-17 JP JP2023536859A patent/JP2024503784A/ja active Pending
- 2021-12-17 US US17/554,276 patent/US12325752B2/en active Active
- 2021-12-17 KR KR1020237024056A patent/KR20230132468A/ko active Pending
- 2021-12-17 AU AU2021401415A patent/AU2021401415A1/en active Pending
- 2021-12-17 CN CN202180093936.1A patent/CN116964101A/zh active Pending
- 2021-12-17 WO PCT/US2021/064073 patent/WO2022133239A1/en not_active Ceased
- 2021-12-17 MX MX2023007023A patent/MX2023007023A/es unknown
- 2021-12-17 CA CA3202629A patent/CA3202629A1/en active Pending
-
2023
- 2023-06-09 CL CL2023001680A patent/CL2023001680A1/es unknown
- 2023-07-17 CO CONC2023/0009498A patent/CO2023009498A2/es unknown
-
2025
- 2025-05-13 US US19/206,976 patent/US20250333524A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7375122B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| JP7781859B2 (ja) | 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質 | |
| CA3089653A1 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| CN111417653A (zh) | Cd47抗原结合分子 | |
| JPWO2019129221A5 (enExample) | ||
| WO2022105914A1 (zh) | Cd70抗体及其应用 | |
| JP7471224B2 (ja) | Ｈ因子増強抗体及びその使用 | |
| JP2010501164A5 (enExample) | ||
| WO2021249542A1 (en) | Antibodies binding tnfr2 and uses thereof | |
| JPWO2022175255A5 (enExample) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP2025165991A (ja) | 腎疾患における抗幹細胞因子抗体及びその使用方法 | |
| TWI834254B (zh) | α-烯醇酶拮抗劑治療纖維化疾病之用途 | |
| JPWO2022133239A5 (enExample) | ||
| JPWO2022268192A5 (enExample) | ||
| JPWO2021042019A5 (enExample) | ||
| JPWO2021202590A5 (enExample) | ||
| WO2019230869A1 (ja) | 抗ヒトｔｌｒ７抗体 | |
| JPWO2023098888A5 (enExample) | ||
| JPWO2019140216A5 (enExample) | ||
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| JPWO2021163170A5 (enExample) | ||
| JPWO2021207072A5 (enExample) | ||
| JPWO2023078382A5 (enExample) |